No abstract

Purpose: Onopordon acanthium L. is known for its medicinal properties. Our recent study showed that its seed extract is a novel natura angiotensin-converting-enzyme inhibitor (ACEI). This study was carried out to investigate its possible antihypertensive effects in patients receiving losartan.Methods: This uncontrolled clinical trial was carried out among 20 patients (30-60y) with uncontrolled hypertension despite receiving 50 mg losartan (stage I & II) in two hospitals in Iran. After completing informed consent, patients were treated by 2 capsules [each 1g of Onopordon acanthium seed extract (OSE)] as add-on therapy, two times per day.Results: 18 patients completed the study (50.94 ±8.37y). Mean systolic blood pressure (SBP) at the baseline was 151.9 ± 13.74mmHg and at the end of the study, it was 134.6 ± 18.25 mmHg and mean diastolic blood pressure (DBP) was 97.41 ± 10.36 at the baseline and was 85.71 ± 7.481 after 8 weeks. OSE significantly reduced SBP and DBP at the end of 8 weeks (P=0.003, 95% CI: -19.7, -15.1; P=0.0006, 95% CI: -10.23, -13.15; respectively). No evidence of hepatic or renal toxicity was detected.Conclusion: Based on the results of this study OSE has antihypertensive property with no significant adverse effects. However, because of the low number of samples, this medication may be not safely administered. The results of this study could be the basis for further studies with larger sample size. IRCT registration number: IRCT2013020712391N.

No abstract

Objective: The aim of this study was to determine the association between previously documented risk factors such as recurrent pyelonephritis with the incidence of renal scarring after acute pyelonephritis in children. Conclusions: According to our findings, presence of VUR and recurrent pyelonephritis are independently associated with a higher incidence of renal scarring.

The aim of the present study was to evaluate the association between a subjective measure of physical activity assessed by a Visual Analogue Scale (VAS) and dyslipidemia in an elderly population of Iran. A total of 74 elderly subjects (39 males) aged 65 years and older who referred to the Cardiovascular Department of the Hospital were studied. Physical activity was assessed on a 100 mm VAS according to which patients were then divided in to two groups active (activity score > or = 50; n = 31) and inactive (activity score < 50; n = 43). Body Mass Index (BMI), systolic and diastolic blood pressure, triglycerides, total cholesterol, Low-Density Lipoproteins (LDL) and High-Density Lipoproteins (HDL) were measured by standard methods. TG (p = 0.021) and LDL (p = 0.006) were significantly higher and HDL was significantly lower (p = 0.028) in the inactive group. No significant associations were found for other variables. As the first report from Iran, present results are important given the race differences that exist in response of plasma lipids to exercise training. Limitations of the present study include its cross-sectional, rather than prospective, structure and the relatively small sample size. It remains to be seen whether VAS can be used as a rapid screening tool for the presence of dyslipidemia in the elderly.

According to our findings, presence of VUR and recurrent pyelonephritis are independently associated with a higher incidence of renal scarring.

In this study the warfarin level in the plasma of 60 patients receiving different dosage regimens of warfarin were determined by HPLC. The corresponding prothrombin times (PT) were also measured. The steady state plasma level of warfarin in 10 healthy volunteers was 900.7+/-158.21 ng/ml. A mean dose of 3.79+/-1.02 mg of warfarin corresponded to a therapeutic level of 1193.81+/-300.35 ng/ml with a mean PT of 20.13+/-0.69 s. The results of this study suggest that Iranian subjects are more sensitive to warfarin than North American and European subjects, but have responses very similar to those of Asians. Dietary, ethnic and geographical factors as well as differences in drug dispensition may be the cause of the observed dosage variability of warfarin.

No abstract